Literature DB >> 26669640

Prevalence of Early Posttraumatic Seizures in Children With Moderate to Severe Traumatic Brain Injury Despite Levetiracetam Prophylaxis.

Melissa G Chung1, Nicole F O'Brien.   

Abstract

OBJECTIVES: To evaluate the prevalence of early seizures after levetiracetam prophylaxis in children with moderate to severe traumatic brain injury.
DESIGN: Prospective observational study.
SETTING: Level 1 pediatric trauma center. PATIENTS: We enrolled 34 patients between the ages of 0-18 years with moderate to severe traumatic brain injury admitted to the PICU at a level 1 trauma center who received levetiracetam for early posttraumatic seizure prophylaxis.
MEASUREMENTS AND MAIN RESULTS: Primary outcome was the prevalence of early posttraumatic seizures that were defined as clinical seizures within 7 days of injury. In 6 of 34 patients (17%), clinical seizures developed despite levetiracetam prophylaxis. An additional two patients had nonconvulsive seizures. This prevalence is similar to that reported in the literature in this patient population who do not receive seizure prophylaxis (20-53%) and is higher than that in patients who receive phenytoin prophylaxis (2-15%). Patients with early posttraumatic seizures were younger (median age, 4 mo) (p < 0.001) and more likely to have suffered from abusive head trauma (p < 0.0004).
CONCLUSIONS: Early clinical posttraumatic seizures occurred frequently in children with moderate to severe traumatic brain injury despite seizure prophylaxis with levetiracetam. Younger children and those with abusive head trauma were at increased risk of seizures. Further studies are needed to evaluate the efficacy of levetiracetam before it is routinely used for seizure prophylaxis in these children, particularly in young children and those who have suffered from abusive head trauma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26669640     DOI: 10.1097/PCC.0000000000000588

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  8 in total

Review 1.  Levetiracetam Versus Phenytoin for Seizure Prophylaxis Following Traumatic Brain Injury: A Systematic Review and Meta-Analysis.

Authors:  Yong Yang; Fangshuo Zheng; Xin Xu; Xuefeng Wang
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

Review 2.  Management of the Pediatric Neurocritical Care Patient.

Authors:  Christopher M Horvat; Haifa Mtaweh; Michael J Bell
Journal:  Semin Neurol       Date:  2016-12-01       Impact factor: 3.420

3.  Continuous electroencephalography in pediatric traumatic brain injury: Seizure characteristics and outcomes.

Authors:  Jarin Vaewpanich; Karin Reuter-Rice
Journal:  Epilepsy Behav       Date:  2016-08-05       Impact factor: 2.937

4.  Early Post-traumatic Seizure Occurrence in Pediatric Patients Receiving Levetiracetam Prophylaxis With Severe Traumatic Brain Injury.

Authors:  Meghan J Kolf; Christopher C McPherson; Kara S Kniska; Caitlyn M Luecke; Michael A Lahart; Jose A Pineda
Journal:  J Pediatr Pharmacol Ther       Date:  2020

5.  Early Seizure Prophylaxis in Traumatic Brain Injuries Revisited: A Prospective Observational Study.

Authors:  Desmond Khor; Jinglan Wu; Quanqiu Hong; Elizabeth Benjamin; Shuiming Xiao; Kenji Inaba; Demetrios Demetriades
Journal:  World J Surg       Date:  2018-06       Impact factor: 3.352

6.  Levetiracetam for Pediatric Posttraumatic Seizure Prophylaxis.

Authors:  Dragos A Nita; Cecil D Hahn
Journal:  Pediatr Neurol Briefs       Date:  2016-03

7.  Early Use of Antiseizure Medication in Mechanically Ventilated Traumatic Brain Injury Cases: A Retrospective Pediatric Health Information System Database Study.

Authors:  Kelly D Haque; Zachary M Grinspan; Elizabeth Mauer; Marianne E Nellis
Journal:  Pediatr Crit Care Med       Date:  2021-01-01       Impact factor: 3.624

Review 8.  Advances and Future Directions of Diagnosis and Management of Pediatric Abusive Head Trauma: A Review of the Literature.

Authors:  A M Iqbal O'Meara; Jake Sequeira; Nikki Miller Ferguson
Journal:  Front Neurol       Date:  2020-02-20       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.